Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?

The company has sought to develop antibodies purpose-built for delivering radiotherapy rather than repurposing existing antibodies for that purpose, as some other players have done.

The US firm has announced positive survival data from a Phase III trial of it radioligand therapy, Iomab-B, in acute myeloid leukemia patients prior to bone transplant, improving its cost-effectiveness case and commercial strategy.

The US firm’s lead asset has impressed as a conditioning regimen for AML patients undergoing bone marrow transplant, boding well for an ongoing US filing as the firm works to disrupt the transplant space across a range of blood cancers.